Tech Company Financing Transactions

Regado Biosciences Funding Round

On 12/20/2012, Regado Biosciences raised $51 million in Series E funding from RusnanoMedInvest, Aurora Funds and Baxter Ventures.

Transaction Overview

Company Name
Announced On
Transaction Type
Venture Equity
Series E
Proceeds Purpose
Proceeds from the financing will support Regado's REGULATE -- PCI Phase 3 clinical study of REG1. This is the company's lead development program for REG1 in arterial thrombosis and is being developed for use in percutaneous coronary intervention (PCI) in the acute coronary syndrome (ACS) population. Regado is also pursuing an additional parallel development program for REG1 for use in Open Heart Surgery. While the vast majority of the funding will be used for the Phase 3 development of REG1 for PCI, some funding will be used to advance other development programs in the Regado pipeline such as REG1 for TAVI (transaortic valve implantation) and REG3 in diabetic vasculopathy.

Company Information

Company Status
Mailing Address
701 Gateway Blvd. 300
San Francisco, CA 94080
Email Address
Regado (NASDAQ: RGDO) is a spin-out of the Department of Surgery at Duke University Medical Center. Regado's technology enables the rational design of drug-antidote pairs against any target accessible to the bloodstream.
Regado Biosciences LinkedIn Company Profile
Social Media
Regado Biosciences Company Twitter Account
Company News
Regado Biosciences News
Regado Biosciences on Facebook
Regado Biosciences on YouTube

Management Team

Email & Social
Chief Executive Officer
Laurent Fischer
  Laurent Fischer LinkedIn Profile  Laurent Fischer Twitter Account  Laurent Fischer News  Laurent Fischer on Facebook
Chief Financial Officer
Christopher Peetz
  Christopher Peetz LinkedIn Profile  Christopher Peetz Twitter Account  Christopher Peetz News  Christopher Peetz on Facebook
Chief Medical Officer
Eric Lefebvre
  Eric Lefebvre LinkedIn Profile  Eric Lefebvre Twitter Account  Eric Lefebvre News  Eric Lefebvre on Facebook
Chief Operating Officer
Helen Jenkins
  Helen Jenkins LinkedIn Profile  Helen Jenkins Twitter Account  Helen Jenkins News  Helen Jenkins on Facebook



Browse more venture capital transactions:

Prev: 12/20/2012: VeraLight venture capital transaction
Next: 12/20/2012: Signifyd venture capital transaction


Share this article


Where The Data Comes From

We do our best to report on every notable VC transaction. VC transactions reported here are sourced from a variety of public sources. The data comes to us via our partnership with, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary